

I NO:27, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:65, SEQ ID NO:70 and SEQ ID NO:76 in a BL21(DE3)LysS E coli host cell wherein the prokaryotic expression vector includes a T7 promoter thereby making a soluble botulinum toxin.

REMARKS

The new claims 113 to 134 are fully supported in the specification and include no new matter.

Support for these claims may be found in, for example, Examples 30, 33, 35, 41, 45, 46, 47, 48 and 49.

The Examiner has indicated in a telephone interview on October 3, 2002 that new claims directed to methods of making botulinum toxins will be considered. The present claims are directed to such methods. Therefore, applicant submits that claims 113 to 134 are allowable and respectfully requests the Examiner to pass the above identified application to issuance at an early date. Should any matters remain unresolved, the Examiner is requested to call (collect) applicant's attorney at the telephone number given below.

Respectfully submitted,



Frank J. Uxa
Attorney for Applicants
Reg. No. 25,612
4 Venture, Suite 300
Irvine, CA 92618
(949) 450-1750
Facsimile (494) 450-1764